2013-09-18 USP Stability 1 Regulations

Stability Program for
Ph ti l P d t Pharmaceuticals Products
September 2013 p
Presented for US Pharmacopeia
Copyright 2013 The United States Pharmacopeial Convention (USP)
12601 Twinbrook Parkway, Rockville, MD 20852
All rights reserved.
Critical Stability Systems
Regulations Procedures Regulations
(I)
Procedures
(II)
Stability Systems
Operations
(III)
Investigations
(IV)
Copyright USP. All rights reserved. 3
Agenda Day One
I. Understanding cGMPs of Stability Testing
Requirements
C iti l l f D St bilit Critical role of Drug Stability
Impact of Chinese GMPs on Stability
Impact of 21 CRF 211 on Stability Impact of 21 CRF 211 on Stability
ICH process and Q1AR2
Stability protocol for global submission
II. Developing Stability Indicating Test Methods
ICH Q2 A/B on Validation ICH Q2 A/B on Validation
USP <1225> Validation
Method verification based on USP<1226>
Copyright USP. All rights reserved.
Stability-indicating test methods
4
Agenda Day Two
III. Critical Stability Operations
Critical steps of Stability Process
Reduce testing with bracketing and matrixing
Benefits and drawbacks of bracketing and matrixing
St bilit D t E l ti Stability Data Evaluation
IV Conduct Out-of-Spec investigation for Stability IV. Conduct Out-of-Spec investigation for Stability
Results
FDA draft guidance on OOS and FDA Guides to
inspection
Analysts and supervisors roles in OOS investigation
O t f T d f St bilit D t
Out-of-Trend for Stability Data
Determine Corrective Actions/Preventive Actions
5
I Understanding cGMPs of I. Understanding cGMPs of
Stability Testing Requirements
Critical Stability Systems
Regulations Procedures Regulations
(I)
Procedures
(II)
Stability Systems
Operations
(III)
Investigations
(IV)
Types of Medications
Product Development
cGMPs
Regional
GMPs
Product
manufactured
in 1 Country
Brazil
ICH
WHO
ASEAN
Latin
America
Product
marketed
in 150+
Brazil
INDIA
WHO
ASEAN
in 150+
Countries
Regulations
Interpretations
Cultural differences
9
Recent inspection data (2012)
Inadequate Lab Controls
Others
21%
Inadequate Lab Controls
15%
Lack of/Inadequate SOPs
Inadequate Process
Validation
4%
Lack of/Inadequate SOPs
10%
Stability Program
4%
QA Systems
9%
Process Validation
4%
Raw Materials
4%
Deficiencies in
Records/Reports
7%
Metrology Program
7%
Production/Process
Controls
System Qualification
5%
Test Methods
4%
4%
10
7%
6%
Price of Medicines
On average 5 out of 5000 new drug candidates are
tested in human and only one (1) is approved.
Average cost of bringing one medicine on the market is
800M to 1.2 Billions
It t k 10 12 t di d d l It takes 10-12 years to discover and develop a new
medicine
Cost of research increase significantly Cost of research increase significantly
Cost of law suits and litigations
Cost of marketing and advertising
Stability Goals
ACTIVE PHARMACEUTICAL INGREDIENT (API)
To establish a retest date for API
Data to support submission of drug product Data to support submission of drug product
DRUG PRODUCT
To establish a shelf life for the commercial product
Drug Product Stability
Stability characteristics of API or Drug Product is a
critical quality attribute of pharmaceutical product
St bilit St di d t t th d l t f Stability Studies are used to support the development of
necessary medical supplies
Critical Role of Drug Stability
Safety and efficacy of drug product are established
during development via clinical studies
Q lit i t bli h d f id tif t th lit d Quality is established for identify, strength, quality and
purity (CFR 211.137)
If drug product stability changes beyond established If drug product stability changes beyond established
acceptance criteria, established safety and efficacy are
no longer applicable.
Stability Data are used to:
Establish how product changes over time under
iti l i t l f t (t t h idit critical environmental factors (temperature, humidity
and light)
Determine appropriate product specifications Determine appropriate product specifications
Select marketing container closure system
Determine appropriate storage conditions pp p g
Justification of expiry of commercial product
Change of Drug Stability
Change of Drug Stability would risk patient safety
Quality of finished products decrease
Potential sub-potent or over-dose products
Potential toxic unknown impurities
U t ll d d t i ti ti d t Uncontrolled process product investigation product
recalls
cGMP violations consent decree criminal cGMP violations consent decree criminal
prosecution
Factors affecting Drug Stability
API related:
Stability of the API from storage
Interaction between the API and excipient FD
Effect of storage (temperature, humidity and light)
Process related:
Selection of different dosage form
Manufacturing process of drug product (DP)
Selection of marketing image
Packaging related:
Selection of container closure packaging system
Handling of DP
Distribution of DP
M k ti i Marketing regions
DRUG DEVELOPMENT PROCESS
Excipients
DRUG
Excipient compatibility
Formulation interaction
DRUG
PRODUCT
API
FORMULATION
DEVELOPMENT
PACKAGING
SELECTION
DEVELOPMENT
FINAL
PACKAGED
API Stability
Process impurity
PRODUCT
Packaging interaction
Storage conditions
Storage configuration
Purpose of Stability Testing
The purpose of stability testing is to provide evidence
on how the quality of a drug substance or drug product
varies with time under the influence of a variety of varies with time under the influence of a variety of
environmental factors such as temperature, humidity
and light.
Stability testing permits the establishment of
recommended storage conditions retest periods and recommended storage conditions, retest periods, and
shelf-lives.
ICH harmonized Tripartite Guideline for Stability Testing of New Drug Substances
and Products [ICH Q1AR2]
GMP 21 CFR 211 GMP - 21 CFR 211
PART 211--cGMP Practices for Finished Pharmaceuticals
Sec. 211.1 SCOPE (a) The regulations in this part
contain the minimum current GMP practice for
preparation of drug products for administration to p p g p
humans or animals.
PART 211--cGMP Practices for Finished Pharmaceuticals
Sec. 211.137 EXPIRATION DATING
(a) To assure that a drug product meets applicable
standards of identity strength quality and purity at the standards of identity, strength, quality, and purity at the
time of use, it shall bear an expiration date determined
by appropriate stability testing described in Sec.
211.166. 211.166.
21 CFR 211.166 - Stability Testing
Stability program must be written and followed:
(a) used in determining appropriate storage
conditions and expiration date.
Written program must include: Sample size and test
intervals Storage conditions for samples intervals, Storage conditions for samples,
21 CFR 211.166 - Stability Testing
Stability program must be written and followed (contd):
Reliable, meaningful, and specific test methods,
Testing of drug product in marketed container,
Testing of drug product for reconstitution at
dispensing time and reconstituted time dispensing time and reconstituted time.
211.166 Stability Testing
(b) An adequate number of batches must be tested
to determine an appropriate expiration date. A
d f h d t t b i t i d record of such data must be maintained.
211.166 Stability Testing
Accelerated studies, combined with basic stability
information on the components, drug products, and
container closure system may be used to support container-closure system, may be used to support
tentative expiration dates.
Full shelf-life studies if not available are being Full shelf life studies, if not available, are being
conducted.
USP General Information Chapters
Three critical components of Documentary Standards
1. Monographs
2. General Chapters
3. General Notices
USP General Information Chapters
C i f h 1000 d d Consist of chapter <1000> and upwards
Chapters provide information they contain no
standards tests assays nor other mandatory standards, tests, assays, nor other mandatory
specifications, with respect to any Pharmacopeial
articles
<1150> Pharmaceutical Stability - Obsolete
Apply to drug dosage form
Chemical, physical & micro integrity of the unit
Shelf life = initial preparation to expiration
Specifications (identity, strength, quality and purity) p ( y, g , q y p y)
throughout shelf life
Influenced by environmental conditions (temperature,
light, air, and humidity)
REMOVED from USP34.
Controlled Room Temperature
Labeled controlled room temperature or upto 25
o
Maintain MKT not more than 25

o
I t ti l id li 25 / 2 t 60 / 5% RH International guideline 25 +/- 2
o
at 60 +/- 5% RH
Accelerated 40 +/- 2
o
at 75 +/- 5% RH
MKT MKT
<1150> Pharmaceutical Stability was removed
Added to General Notices
Mean Kinetic Temperature
H = the heat of activation for the degradation reaction; assumed to be 83.144 kJ per mol
unless more accurate information is available from experimental studies.
R = 8.3144 10
-3
kJ per degree per mol (the universal gas constant)
T
1
= the average temperature, in degrees Kelvin, during the first time period
1
T
2
= the average temperature, in degrees Kelvin, during the second time period
T
n
= the average temperature, in degrees Kelvin during the nth time period
<1150> Ph ti l St bilit d <1150> Pharmaceutical Stability was removed
Added to <1079> Good Storage and Shipping Practices
Drug Product Distribution
Dispensing Doctor
(6)
Repackager
(2)
Innovator
Wholesalers &
Pharmacy (4)
Chain Drug Store
Generic
Mfg
(1)
o esa e s &
Distributors
(3)
Government
Independent Hospital
Pharmacy
Patient
(7)
(1)
Clinics
Nursing Homes
Mail Order
Sample
Distribution (5)
Shipping
Distribution (5)
ICH St bilit Q1A (R2) ICH Stability -- Q1A (R2)
34
International Conference on Harmonization (ICH)
Purpose: To provide a forum for dialogue between
Health Authorities and Industry on the disparities with
respect to requirements of US, Europe and Japan respect to requirements of US, Europe and Japan
Global Stability Requirements
Global Climatic Zones
Zone I: Temperate less than 20
o
C p
e.g. Germany, Russia, Canada
Zone II: Sub-tropical with possible high humidity
averaging 20.5-24
o
C
e.g. France, Peru, Australia, USA
Zone III: hot and dry
e.g. Botswana, Chad, Syria, Iraq
Z IV h t d h id Zone IV: hot and humid
averaging more than 24
o
C
e g Taiwan Singapore India parts of South America
e.g. Taiwan, Singapore, India, parts of South America
International Conference on Harmonization (ICH)
Goal: To develop guidelines that are acceptable for regulatory
review by US, Europe and Japan
ICH Steering Committee: 6 Parties
PhRMa, FDA,
EFPIA, EU,
MHLW, JPMA
and IFPMA (non voting member) and IFPMA (non voting member)
Official Observers: Canada, WHO, EFTA
Interested Parties: Pharmacopeia, IGPA, WSMI
ICH participants
FDA US Food & Drug Administration
PhRMA Pharmaceutical Research and Manufacturers of America
EU E ropean Union EU European Union
EPPIA European Federation of Pharmaceutical Industries and
Associations
MHLW Ministry of Health, Labour and Welfare
JPMA Japan Pharmaceutical Manufacturers Association
IFPMA International Federation of Pharmaceutical Manufacturers IFPMA International Federation of Pharmaceutical Manufacturers
& Associations
WHO World Health Organization
EFTA - The European Free Trade Association EFTA - The European Free Trade Association
WSMI World Self-Medication Industry
IGPA International Generic Pharmaceutical Alliance
5 Major Steps in ICH Process
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5
Consensus
Building
By EWG
Regulatory
Consultation
Implemen-
tation
By EWG
Consensus
Agreed
by 6 parties
Adoption
of ICH
Guideline
Harmonizing Stability Storage Conditions
Registration requirements
Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies and Best
Practices, K. Huynh-Ba (ed.), Springer, November 2008, Chapter 2.
Distribution of nations into different climatic zones
Region Zones I & II Zone III & IV
European All countries European All countries -
American Chile, Canada, United States
Brazil, Jamaica,
Venezuela
Asian China, Japan, Turkey
India, Philippines, Sri
Lanka
S th Af i Z bi B t Gh
African
South Africa, Zambia,
Zimbabwe
Botswana, Ghana,
Uganda
Australian / Oceanic Australia, New Zealand Fiji, Papua - New Guinea j p
ICH Storage Conditions
I ntended
Storage
Condition
Stability Studies Study Condition
Submission
Requirement
Condition
Room
Long Term 25 C/ 60%RH 12 months
I ntermediate* 30 C/ 65%RH 6 months
Temperature
Intermediate 30 C/ 65%RH 6 months
Accelerated 40 C/ 75%RH 6 months
Refrigerated
Long Term 5 C/ ambient 12 months
Accelerated 25 C/ 60%RH 6 months
Freezer Long Term - 20 C/ ambient 12 months
* Significant change
Selection of Batches
API DRUG PRODUCT
Selection of
Batches
3 batches
(pilot scale)
3 batches/strength
(2 pilot + 1 lab scale)
Manufacturing
P
Representative of Commercial Production
Process
Representative of Commercial Production
Acceptance
Criteria
Similar to those used in pre-clinical and clinical
studies
Container Closure Same to proposed commercial packaging
Testing
Frequency
Long Term: 0, 3, 6, 9, 12, 18, 24 mo and
annually
Intermediate: to 12 months minimum4 points Frequency Intermediate: to 12 months, minimum 4 points
Accelerated: to 6 months, at least 3 points
Stability
Commitment
Must commit to put up 3 production batches
with same protocols Commitment with same protocols
Significant Change
API
Significant change is defined as failure to meet the
specification.
1. A 5 percent potency change from the initial assay
value;
2 Any specified degradant exceeding its acceptance
Drug
2. Any specified degradant exceeding its acceptance
criteria
3. Failure to meet acceptance criteria for appearance and
physical properties (e g color phase separation
g
Product
physical properties (e.g., color, phase separation,
resuspendibility, delivery per actuation, caking,
hardness); and as appropriate to the product type;
4 Th H di it t it i d 4. The pH exceeding its acceptance criteria; and
5. Dissolution exceeding the acceptance criteria for 12
dosage units.
Other Stability Storage Condition
Other stress conditions
30
o
C/90%RH (3-6 months)
50
o
C (3-6 months)
60
o
C (3-6 months)
Photostability (Q1B) Photostability (Q1B)
Freeze-Thaw
Thermal Cycling
Example of temperature excursion studies:
Thermal Cycling
e.g., 40
o
C, 4 days, then 25
o
C/60%RH, 3 days
Repeat cycle twice
Freeze-Thaw Cycling Freeze-Thaw Cycling
e.g., -20
o
C, 4 days then 25
o
C/60%RH, 3 days
Repeat cycle twice
Perform full testing at end of complete cycling
Special Package
Liquids in Semi-Permeable Containers:
o Long-Term: 25
o
C/405%RH (Zone I/II) or
30
o
C/355%RH (all zones)
o Intermediate: 30
o
C/655%RH
o Accelerated: 40
o
C/NMT25%RH
*or 25
o
C/60RH and calculate wt. loss equiv. to 25
o
C/40RH or 25 C/60RH and calculate wt. loss equiv. to 25 C/40RH
**if 30
o
C/35RH is long-term condition, no intermediate
condition is needed
Alternative approach when thermal cycling and
free-thaw cycling have not been done
Evaluate MKT
Review Forced Degradation data
E l t St t di Evaluate Stress studies
Key Factors of Q1A(R2)
Must use Validated Stability-Indicating analytical
methods
Methods must cover physical, chemical, biological and
microbiological attributes
Studies evaluated under thermal and elevated humidity
to cover storage, shipment and subsequent use
Key Factors of Q1A(R2) (contd)
Accelerated and intermediate used to evaluate impact of
short-term excursions.
Acceptance criteria should include individual and total
upper limits for impurities and degradation products
No formal statistical analysis is needed if data show little
degradation or variability.
Photostability (Q1B)
Expose sample to a range of radiation that simulates sunlight.
Specification: Visible radiation is not less than 1 2 million lxh Specification: Visible radiation is not less than 1.2 million lxh
and UV is not less than 200 W h/m
2
o Option I:
o single radiation source
o more difficult to control temperature/humidity o more difficult to control temperature/humidity
o sample will overexposed to UV
o Option II :
o two radiation sources, one for visible radiation and one
for UV
o easier to control temperature/humidity
o easier to control temperature/humidity
Q1B Photostability
Sequence of studies:
Drug products fully exposed, if unacceptable
h d t t t change, proceed to next step
Drug products in the intermediate pack, if
unacceptable change, proceed to next step unacceptable change, proceed to next step
Drug products in the marketing pack
Recommendation on labeling or packaging
ICH Guidances
Q1C Stability Testing of New Dosage Forms (May 1997);
Q1D Bracketing and Matrixing Designs for Stability Testing of New
Drug Substances and Products (January 2003);
Q1E E l ti f St bilit D t (J 2004) Q1E Evaluation of Stability Data (June 2004);
Q1F Stability Data Package for Registration Applications in Climatic
Zones III and IV, Revision 1 (July 2004) - withdrawn
Q6A Specifications: Test Procedures and Acceptance Criteria for Q6A Specifications: Test Procedures and Acceptance Criteria for
New Drug Substances and New Drug Products: Chemical
Substances (December 2000);
Q6B Specifications: Test Procedures and Acceptance Criteria for Q6B Specifications: Test Procedures and Acceptance Criteria for
Biotechnological/Biological (August 1999);
Q7A Good Manufacturing Practice Guidance for Active
Pharmaceutical Ingredients (August 2001); g ( g );
Q8 Pharmaceutical Development (Draft) (February 2005);
M4: Common Technical Document (CTD) for the Registration of
Pharmaceuticals for Human Use (CTD) (October 2001);
Ref: US FDA, Guidance for Industry on Chemistry, Manufacturing, and Controls Information; Withdrawal and Revision of Seven
Guidances, Federal Register 71 (105), 31194-31195 (June 1, 2006) DOCID: fr01jn06-73
GMP I di GMP - India
Personnel
Head of QC lab is independent of the manufacturing unit
Personnel of QC and QC are qualified and experienced
Written duties must be done and following strictly
Number of people must be adequate and proportional to p p q p p
workload
Everyone has appropriate training and regular in-service
training
Equipment
Located, designed, constructed, adapted and maintained
to suite operations
Design must minimize risk of errors and allow effective
cleaning and maintenance.
All t h l b k All must have logbook
Balances to be calibrated and checked
Part of production equipment that come in contact with
product cant be reactive, additive or adsorptive that
effect product quality p q y
Defective equipment must be removed and appropriate
labeled.
Documentation
Define specs for all materials, manufacturing process,
and control process
Provide audit trail that permit investigation
Documents designed, prepared, reviewed and controlled
Documents must be approved, signed and dated by
appropriate and authorized personnel.
Document specify title, nature and purpose.
Record complete at time of operation
Data recorded by electronic: data entry, change or
deletion, etc..
Validation
Conducted as per a pre-defined protocol
Include validation of processing, testing and cleaning
procedures
Written report summarizing results and conclusions
Significant changes to equipment, materials, methods
shall be validated.
WHO St bilit G id li WHO Stability Guidelines
WHO Stability guidelines
Working document QAS/06.179/Rev.2 Stability Testing of Active
Pharmaceutical Ingredients and Pharmaceutical Products divides
countries with tropical and subtropical moist climates into: p p
Zone IVA with long-term conditions: 30
o
C 2
o
C and 65% 5%
RH
Z IVB ith l t diti 30 C 2 C d 75% 5% Zone IVB with long-term conditions: 30
o
C 2
o
C and 75% 5%
RH, which is the worst case and the recommended long-term
condition for the Prequalification Project
Each individual Member State within the former Zone IV would need to
indicate whether its territory should be classified as Zone IVa or Ivb
Q1F Withdrawn 2006
FDA Withdrawn - Draft Stability Guidelines in 2006
Association of Southeast Asian Nations (A.S.E.A.N.)
Cambodia,
Brunei,
Indonesia Indonesia,
Laos,
Malaysia,
Philippines, Philippines,
Singapore,
Thailand,
Vietnam.
Climate Zone Classification
Country Climatic Zones Assigned To
Afghanistan I, II II
Algeria II, III II (a)
Angola II, IV II
Argentina II II Argentina II II
Armenia I, II II (a)
Australia I, II, III, IV II
Azerbaijan I, II II
Bahrain IV IV
Bangladesh IV IV
Barbados IV IV
Belize IV IV
Benin IV IV
Bolivia I, II, IV II (a)
Botswana III III
B il II IV IV Brazil II, IV IV
Bulgaria I, II II
Burkina Faso IV IV
Burundi IV IV
Cameroon IV IV
Canada I I
Canary Islands II II
Central African Republic IV IV
Chad III, IV III
Chile I, II II
61
China I, II, IV II (a)
Columbia IV IV
Congo II, IV IV
Re-test Period
After this period a batch of API destined for use in the
manufacture of a pharmaceutical product should be re-
tested for compliance with the specification and then used tested for compliance with the specification and then used
immediately. A batch of active pharmaceutical ingredient
can be re-tested multiple times and a different portion of
the batch used after each re-test, as long as it continues to
comply with the specification.
A retest period should be proposed on the basis of stability A retest period should be proposed on the basis of stability
results and may be extended to five years
Shelf-Life (Expiration Dating Period)
The period of time during which a pharmaceutical product,
if stored correctly, is expected to comply with the
specification as determined by stability studies on a specification as determined by stability studies on a
number of batches of the product. The shelf-life is used to
establish the expiry date of each batch.
Stability Protocol
Study described in a written protocol
Protocol extented to the end of retest period
Similar Protocol used for long-term studies and primary
batches
Data must be documented in a report
API Batches should be manufactured from different
batches of intermediates
DP batches should be made from different API batches
Typical Global Stability Protocol
TEMP
TZ
1 2 3 6 9 12 18 24 36
HUMIDITY
TZ
Mo Mo
3
Mo
6
mo Mo Mo
8
Mo mo
36
Mo
25 C 25 C
60%RH
X X X X X X X X
30 C
65%RH
X X X X (X) (X) (X)
(30 C
75%RH)
X X X X X X X X
40 C
75%RH
X (X) X X
75%RH
( )
50 C X
5 C H O L D
Stress Testing
Drug substance (API)
Studies undertaken to elucidate the intrinsic
stability of the active pharmaceutical ingredient. Such
testing is part of the development strategy and is normally
carried out under more severe conditions than those used
for accelerated testing.
Drug Product (DP) g ( )
Studies undertaken to assess the effect of severe
conditions on the pharmaceutical product. Such studies
include photostability testing and specific testing on c ude p o os ab y es g a d spec c es g o
certain products, (e.g. metered dose inhalers, creams,
emulsions, refrigerated aqueous liquid products).
Goal of stress testing
To validate the stability indicating power of the
analytical procedures.
To identify stability-affecting factors such as ambient
temperature, humidity and light and to select packing
materials, which protect the FPP against such effects. materials, which protect the FPP against such effects.
To identify potential degradants of the API and assess
if they can be formed during manufacture or storage of y g g
the DP.
To select manufacturing process of the DP g p

2013-09-18 USP Stability 1 Regulations

Uploaded by

Copyright:

Available Formats

2013-09-18 USP Stability 1 Regulations

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

2013-09-18 USP Stability 1 Regulations

Uploaded by

Copyright:

Available Formats

What are the main topics covered in the training?

What are some common deficiencies found in stability programs?

Stability Program for

Maintain MKT not more than 25

You might also like